PDF(Pubmed)
Abstract：
The transcription factor Yin Yang 1 (YY1) plays a pivotal role in the pathogenesis of glioblastoma multiforme (GBM), an aggressive form of brain tumor. This review systematically explores the diverse roles of YY1 overexpression and activities in GBM, including its impact on the tumor microenvironment (TME) and immune evasion mechanisms. Due to the poor response of GBM to current therapies, various findings of YY1-associated pathways in the literature provide valuable insights into novel potential targeted therapeutic strategies. Moreover, YY1 acts as a significant regulator of immune checkpoint molecules and, thus, is a candidate therapeutic target in combination with immune checkpoint inhibitors. Different therapeutic implications targeting YY1 in GBM and its inherent associated challenges encompass the use of nanoparticles, YY1 inhibitors, targeted gene therapy, and exosome-based delivery systems. Despite the inherent complexities of such methods, the successful targeting of YY1 emerges as a promising avenue for reshaping GBM treatment strategies, presenting opportunities for innovative therapeutic approaches and enhanced patient outcomes.
摘要：
转录因子阴阳1（YY1）在多形性胶质母细胞瘤（GBM）的发病机制中起着关键作用，一种侵袭性的脑肿瘤.本文系统地探讨了YY1过表达和活性在GBM中的不同作用。包括其对肿瘤微环境（TME）和免疫逃避机制的影响。由于GBM对当前疗法的反应不佳，文献中关于YY1相关通路的各种发现为新的潜在靶向治疗策略提供了有价值的见解.此外，YY1作为免疫检查点分子的重要调节剂，因此，是与免疫检查点抑制剂组合的候选治疗靶标。在GBM中靶向YY1的不同治疗意义及其固有的相关挑战包括使用纳米颗粒，YY1抑制剂，靶向基因治疗，和基于外泌体的递送系统。尽管这种方法固有的复杂性，YY1的成功靶向成为重塑GBM治疗策略的有希望的途径，为创新的治疗方法提供机会，并提高患者的治疗效果。
